Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01382706 · ClinicalTrials.gov registry record · Phase 2
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
A Phase 2 study, sponsored by University of Southern California.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT01382706 is a Phase 2 study that was terminated before completion, run by University of Southern California. The registered enrollment target is 15 participants.
The verdict
NCT01382706, a Phase 2 study, was terminated before completion, sponsored by University of Southern California.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel and lapatinib ditosylate together may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG docetaxel
- OTHER immunohistochemistry staining method
- DRUG lapatinib ditosylate
- GENETIC fluorescence in situ hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2011-06-13 |
| Est. Completion | 2017-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01382706
The ClinicalTrials.gov registry entry for NCT01382706 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 617 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT01382706 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01382706 about?
NCT01382706 is a clinical study titled "Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder". This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor ...
What is the current status of trial NCT01382706?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2011-06-13. Estimated completion is 2017-12-15.
What interventions are being tested in trial NCT01382706?
The interventions under investigation include: laboratory biomarker analysis (OTHER), docetaxel (DRUG), immunohistochemistry staining method (OTHER), lapatinib ditosylate (DRUG), fluorescence in situ hybridization (GENETIC).
Who is sponsoring clinical trial NCT01382706?
This trial is sponsored by University of Southern California, which has 617 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.